Journal article
Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trial
H Smith-Vaughan, B Temple, VT Trang Dai, PT Hoan, HN Loc Thuy, TV Phan, K Bright, NT Toan, DY Uyen, CD Nguyen, J Beissbarth, BD Ortika, ML Nation, EM Dunne, J Hinds, J Lai, C Satzke, TN Huu, K Mulholland
Lancet Regional Health Western Pacific | Published : 2023
Abstract
Background: WHO recommends a three-dose infant pneumococcal conjugate vaccine (PCV) schedule administered as a two-dose primary series with booster (2 + 1) or a three-dose primary series (3 + 0). Data on carriage impacts of these and further reduced PCV schedules are needed to inform PCV strategies. Here we evaluate the efficacy against carriage of four different PCV10 schedules. Methods: Participants within an open-label, randomised controlled trial in Ho Chi Minh City, Vietnam, were allocated to receive PCV10 in a 3 + 1 (2,3,4,9 months, n = 152), 3 + 0 (2,3,4 months, n = 149), 2 + 1 (2,4,9.5 months, n = 250) or novel two-dose (2,6 months, n = 202) schedule, or no infant doses of PCV (two c..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
<STRONG> </STRONG>We thank the study participants and their families, the study staff, and the laboratory staff from the Pasteur Institute of Ho Chi Minh City, the Menzies Child Health team, and the MCRI Translational Microbiology Group. We acknowledge the contributions of Dang Duc Anh, Nguyen Thi Hien Anh, Jonathan Carapetis, Nguyen Thi Kieu Chinh, Lam Trung Duc, Katherine Gould, William Hausdorff, Bernard Hoet, Vu Thi Que Huong (deceased), Tran Thi Kim Ngan, Peter Paradiso, Nguyen Thi Minh Phuong (deceased), Fiona Russell, and Lay Myint Yoshida. We also acknowledge the Victorian Government's Operational Infrastructure Support Program. This work was supported by the National Health and Medical Research Council of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). PCV10 vaccine doses were donated by GlaxoSmithKline Biological SA.